Vivo Capital IX, LLC 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:03 pm Sale | 2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Vivo Capital IX, LLC | 894,826 2.700% | -1,367,374 (-60.44%) | Filing |
| 2023-02-13 5:52 pm Sale | 2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Vivo Capital IX, LLC | 2,262,200 8.500% | -725,131 (-24.27%) | Filing |
| 2022-02-11 5:21 pm Sale | 2021-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Vivo Capital IX, LLC | 2,987,331 14.400% | -257,704 (-7.94%) | Filing |
| 2020-10-28 4:31 pm Purchase | 2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Vivo Capital IX, LLC | 3,245,035 16.200% | 3,245,035 (New Position) | Filing |